RxDoctor Payments Data

Bhavesh Patel, MD

Internal Medicine · Savannah, GANPI 1619976222

Payments from drug & device makers

$6,870in general payments, 2019–2025

Across 529 payments — averaging $12.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Novartis$755
  • Lilly USA, LLC$687
  • AstraZeneca$482
  • AbbVie$418
  • Supernus Pharmaceuticals, Inc.$382
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,80499%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,870 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$183,405
Medicare patients
372
Services billed
6,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$121,137
EliquisApixaban77$75,233
JardianceEmpagliflozin48$70,684
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$51,908
MounjaroTirzepatide20$37,046
TrulicityDulaglutide16$34,395
FarxigaDapagliflozin Propanediol30$29,696
Soliqua 100-33Insulin Glargine/Lixisenatide11$25,727
XareltoRivaroxaban17$19,065
Atorvastatin Calcium708$6,338
Rosuvastatin Calcium531$6,176
Famotidine259$6,154
Levothyroxine Sodium429$5,220
Gabapentin271$5,219
Amlodipine-AtorvastatinAmlodipine/Atorvastatin12$5,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,047$121,13774 claims
PfizerEliquis$289$75,23377 claims
Lilly USA, LLCMounjaro, Trulicity$687$71,44136 claims
Boehringer IngelheimJardiance$266$70,68448 claims
GSKTrelegy Ellipta$36$51,90841 claims
AstraZenecaFarxiga$482$29,69630 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$61$25,72711 claims
AbbVieSynthroid$418$4,36634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →